Tolerability and safety of rituximab (MabThera).

@article{Kimby2005TolerabilityAS,
  title={Tolerability and safety of rituximab (MabThera).},
  author={Eva K Kimby},
  journal={Cancer treatment reviews},
  year={2005},
  volume={31 6},
  pages={456-73}
}
Rituximab, a human/mouse chimeric anti-CD20 antibody, has become part of standard therapy for patients with CD20-expressing B-cell lymphoma, and is currently under investigation for other indications including autoimmune diseases, in particular rheumatoid arthritis (RA). Its characteristic tolerability profile was established soon after clinical testing began and compares favourably with chemotherapy. The majority of patients experience mild to moderate infusion-related reactions (IRRs) during… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 153 extracted citations

At a Glance

View 7 Excerpts
Highly Influenced

Rituximab therapy in malignant lymphoma

Oncogene • 2007
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…